Incivek
(telaprevir)ApprovedSmall molecule
Vertex PharmaceuticalsTelaprevir is used to treat hepatitis C, a viral infection that affects the liver. It works by stopping the hepatitis C virus from reproducing in the body.[2] Incivek is currently approved and in use across 11 indications[4].[1]
Incivek is one of 344 small molecule programs targeting HIV infection. It is currently in Approved.
11
Indications
63
Total Trials
0
Active Trials
343
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
797 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Incivek
Vertex PharmaceuticalsApproved
Ibrance
PfizerPreclinical
Viread
GileadPreclinical
Hepsera
GileadPreclinical
Coreg
Akero TherapeuticsPreclinical
Apatinib
LLaNova Medicines Zhejiang Co., Ltd.
Preclinical
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Preclinical
QL1706
Qilu Pharmaceutical Co., Ltd.Preclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatitis C14 trials
Show 11 more trials
Chronic Hepatitis10 trials
Interaction6 trials
Show 3 more trials
Chronic Hepatitis C Virus Infection4 trials
Efficacy and Safety3 trials
18 more indications
Hepatitis C Virus Infection3 trials
Liver Transplant3 trials
Hepatic Impairment2 trials
TED2 trials
Combination Therapy2 trials
Trial2 trials
Effectiveness1 trial
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
Completed·—·N/A·NCT02113631·50 enrolled
HIV-11 trial
Tacrolimus1 trial
Renal Impairment1 trial
ESS1 trial
HIV1 trial
Adult Subject1 trial
Interleukin1 trial
Regulatory
FDA Approval Timeline[5]
May 23, 2011
INCIVEK
NDA NDA201917
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Incivek drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for telaprevir. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Hepatitis C Virus Serine Protease, NS3/NS4A Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[6]
Patent Cliff
May 30, 2028
Earliest patent expiration — generic entry possible after this date
Patent #Expires
8431615May 30, 2028